分析师 HC Wainwright、BTIG Research 和加拿大皇家银行重申/上调 Verastem 和 Vera Therapeutics 的“买入”评级和目标价格。 Analysts HC Wainwright, BTIG Research, and Royal Bank of Canada reaffirm/raise "Buy" ratings and target prices for Verastem and Vera Therapeutics.
HC Wainwright 重申了 Verastem (VSTM) 的“买入”评级，并设定了 17.50 美元的目标价。 Verastem's (VSTM) "Buy" rating is reaffirmed by HC Wainwright, setting a $17.50 target price. BTIG Research 还重申“买入”评级，目标价为 27.00 美元，而加拿大皇家银行则发布“跑赢大盘”评级，目标价为 32.00 美元。 BTIG Research also restates a "Buy" rating with a $27.00 target price, while Royal Bank of Canada issues an "Outperform" rating with a $32.00 target price. 与此同时，Wedbush 将 Vera Therapeutics （纳斯达克股票代码：VERA）的目标价从 21.00 美元上调至 34.00 美元，维持“中性”评级。 Meanwhile, Vera Therapeutics (NASDAQ:VERA) target price is raised by Wedbush from $21.00 to $34.00, maintaining a "Neutral" rating. 这些分析师的行动是在 Cantor Fitzgerald 和 Oppenheimer 等公司的报道之外进行的。 These analyst actions come in addition to coverage from firms such as Cantor Fitzgerald and Oppenheimer.